Skip to main content
. 2023 Mar 30;41(16):3032–3041. doi: 10.1200/JCO.22.02367

FIG 1.

FIG 1.

Kaplan-Meier plots of the (A) duration of response and (B) overall survival among patients with extranodal natural killer/T-cell lymphoma treated with sugemalimab. The duration of response was determined by the independent radiology review committee for 35 patients who had a response. The Kaplan-Meier curve of overall survival for 79 patients included in the efficacy analysis set. Tick marks indicate censored data. Q3W, once every 3 weeks.